Effect of Allopurinol on Blood Pressure of Adolescents With Newly Diagnosed Essential Hypertension

摘要: Context Hyperuricemia is a predictor for the development of hypertension and commonly present in new-onset essential hypertension. Experimentally increasing uric acid levels using uricase inhibitor causes systemic animal models. Objective To determine whether lowering lowers blood pressure (BP) hyperuricemic adolescents with newly diagnosed Design, Setting, Patients Randomized, double-blind, placebo-controlled, crossover trial (September 2004-March 2007) involving 30 (aged 11-17 years) who had diagnosed, never-treated stage 1 serum ≥6 mg/dL. Participants were treated at Pediatric Hypertension Clinic Texas Children's Hospital Houston. excluded if they 2 or known renal, cardiovascular, gastrointestinal tract, hepatic, endocrine disease. Intervention Allopurinol, 200 mg twice daily 4 weeks, placebo, 2-week washout period between treatments. The order treatments was randomized. Main Outcome Measures Change casual ambulatory pressure. Results For BP, mean change systolic BP allopurinol −6.9 mm Hg (95% confidence interval [CI], −4.5 to −9.3 Hg) vs −2.0 CI, 0.3 −4.3 Hg; P = .009) diastolic −5.1 −2.5 −7.8 −2.4 0.2 −4.1; P = .05) placebo. Mean 24-hour −6.3 −3.8 −8.9 0.8 3.4 −2.9 P = .001) placebo −4.6 (−2.4 −6.8 −0.3 2.3 −2.1 P = .004) Twenty participants achieved normal by criteria while taking participant (P  Conclusions In this short-term, study hypertension, treatment resulted reduction BP. results represent new potential therapeutic approach, although not fully developed strategy due adverse effects. These preliminary findings require confirmation larger clinical trials. Trial Registration clinicaltrials.gov Identifier: NCT00288184